🔗 Share this article

A shadow market for unlicensed slimming drugs is being driven by social media fitness personalities and vendors on communication apps, based on recent findings.

Experimental Drug Gaining Traction Via Social Media

The experimental drug, which remains in research studies, is being advertised by online personalities for its supposed fat-burning effects. Followers are encouraged to message these profiles directly for supplier links, while also obtaining discount codes.

Thriving Trade on Social Networks

Additionally, a flourishing trade exists on messaging services, where groups with thousands of members share “before and after” photos, administration instructions and assertions of next-day British shipping. Sellers promote the substance there before directing customers to other platforms for purchases.

Understanding Retatrutide

This medication is an investigational injectable created by American pharmaceutical company Eli Lilly. The treatment targets three gut hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Early trials indicate it could help patients reduce up to 25% of their total weight. Referred to as the “triple G”, the drug is being promoted digitally as the successor to Ozempic.

Medical Professionals Voice Worries

However, doctors and pharmacists have warned that the sale of what is still an unapproved medication in the UK is worrisome and could lead to users injecting substances of unknown origin.

Several professionals said the demand for retatrutide could be linked to the rising price of approved slimming treatments such as Mounjaro.

Legal Position and Implementation

Marketing retatrutide on social media or Telegram is illegal in the United Kingdom, as it is an unlicensed drug that must not be marketed or supplied for personal consumption under the British medical regulations.

Some content creators attempt to sidestep the regulations by calling to the drug as a “research chemical” or citing it as “not for human consumption”. The substance is not a controlled substance, but advertising and supply can still violate pharmaceutical, advertising, and consumer laws, potentially leading to penalties, prosecution or imprisonment.

Platform Response and Material Removal

According to the social media company, the service has removed violative material and prohibited associated hashtags and query recommendations. The organization stated it was committed to keeping the platform safe and allocating resources in enhancing compliance measures.

Online Trading Activities

Investigations also found groups with up to nine thousand participants selling the experimental drug using Telegram's integrated discovery tool, which operates like a public directory. Entering “retatrutide” instantly brings up channels with numerous of members, populated with images of slimming results, positive testimonials and detailed guides for preparing or injecting at home.

Within moments of joining one group, a vendor posted WhatsApp details, where most purchases take place. The seller provided an instruction manual and promised delivery within two days. When asked whether the product was genuine, one vendor responded: “You can’t be sure.” Another provided a photo of a alleged testing documentation. Not one asked about body mass, medical conditions or past usage.

Item Information and Pricing

Within these communities, messages display black plastic packages with postal service labels, claiming to include new batches. One communication stated: “It took eight of us to load them this morning.”

Buyers can select between dry substance containers, mixed at home with sterile water, or ready-to-use pens typically sold at 160 pounds for 20mg. When asked how long a injector should last, vendors give contradictory answers ranging from a few weeks to “depends on your body”.

Service Oversight and Security Actions

A representative for Telegram stated it actively moderated harmful content on its service including material that encouraged the “misuse of controlled medications”. The company noted that it removed “millions of pieces of harmful content each day”.

Medical Professional Warnings

“People are administering substances they cannot confirm. Although the science behind this drug is sound, these online products may not include what they advertise,” said Jason Murphy, the head of pharmaceutical services at a pharmacy service.

Dr Crystal Wyllie of Asda Online Doctor linked the increase in demand to current price rises for approved weight-loss medications such as Mounjaro. “With prices rising, individuals are using social media. But fake injections are extremely dangerous. You can’t be certain what’s contained or whether the conditions they were produced in was clean,” she explained.

Her staff has previously encountered individuals injured by self-injection from unconfirmed sources. “We recognize the disappointment, but purchasing from Telegram or communication platforms is taking chances with your well-being,” said the doctor. “These substances could be impure or incorrectly dosed.”

Producer Statement

A spokesperson from Eli Lilly said the substance was in third stage clinical trials and had not been reviewed or approved by any regulatory agency anywhere in the world. “Therefore at this point no one can sell [it] for human use,” they said, noting that any product “misleadingly claiming itself as a Lilly experimental substance not yet approved … may subject patients to possibly serious health risks”.